X0306 4 2013-01-02 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532475 Goldberg Mark Alan 128 SPRING STREET, SUITE 520 LEXINGTON MA 02421 false true false false SVP, Product Development Common Stock 2013-01-02 4 M false 4417 0.95 A 4417 D Common Stock 2013-01-02 4 S false 4417 47.52 D 0 D Stock Option (Right to Buy) 0.95 2013-01-02 4 M false 4417 0 D 2019-07-01 Common Stock 4417 12085 D The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 8, 2012. The reporting person was granted two options on 07/01/2009. These options are combined for reporting purposes herein. The first option was to purchase 3,300 Shares. 25% of such Shares vested and became exercisable on 10/10/2009, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. The second was an option to purchase 13,202 Shares. 25% of such Shares vested and became exercisable on 07/01/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $47.01 to $47.82 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Mark Goldberg 2013-01-04